Case Report: Successful treatment of pyoderma gangrenosum-like granulomatous liver disease without skin lesions using a TNF-alpha inhibitor - Summary - MDSpire

Case Report: Successful treatment of pyoderma gangrenosum-like granulomatous liver disease without skin lesions using a TNF-alpha inhibitor

  • By

  • Isabelle Panne

  • Matthias Matter

  • Jürg Vosbeck

  • Matthias von Rotz

  • Alexandra Steinemann

  • Marten Trendelenburg

  • Markus H. Heim

  • Peter Schirmacher

  • Andrea De Gottardi

  • Ansgar W. Lohse

  • Luigi M. Terracciano

  • Christine Bernsmeier

  • June 15, 2026

  • 0 min

Share

Objective:

To report a case of extracutaneous manifestation of pyoderma gangrenosum without skin lesions, emphasizing diagnostic challenges, immunological considerations, and therapeutic implications.

Approach:
    Key Findings:
    • The patient exhibited isolated hepatic and ocular involvement of pyoderma gangrenosum without skin lesions.
    • Histology revealed sterile abscesses and granulomatous inflammation.
    • Successful treatment with a TNF-alpha inhibitor led to complete clinical and biochemical remission.
    Interpretation:

    This case highlights the systemic nature of pyoderma gangrenosum and the potential for hepatic involvement without primary skin manifestations, underscoring the need for clinical awareness.

    Limitations:
    • The rarity of the condition limits generalizability and may affect treatment approaches.
    • Lack of long-term follow-up data on the patient's condition post-treatment.
    Conclusion:

    The case expands the clinical understanding of pyoderma gangrenosum and reinforces the need for awareness of its systemic manifestations.

Original Source(s)

Case Report: Successful treatment of pyoderma gangrenosum-like granulomatous liver disease without skin lesions using a TNF-alpha inhibitor

  • by Isabelle Panne, Matthias Matter, Jürg Vosbeck, Matthias von Rotz, Alexandra Steinemann, Marten Trendelenburg, Markus H. Heim, Peter Schirmacher, Andrea De Gottardi, Ansgar W. Lohse, Luigi M. Terracciano, Christine Bernsmeier

  • June 15, 2026

Related Content

Medical Oddities: A Cancer Clue Some Patients Can’t See

This week’s science roundup shows how hidden signals can shape real outcomes.

Curbing Drug-Related Halitosis for Closer Moments

Individuals who have drug-related halitosis may need to take additional steps to prioritize oral health before intimate encounters.

AI Scribes: Efficiency for Whom?

Unresolved safety, privacy, and regulatory concerns may limit benefits of AI scribes for physicians and patients.